



## Synthesis of 2-oxazolines and related N-containing heterocycles using $[\text{Et}_2\text{NSF}_2]\text{BF}_4$ as a cyclodehydration agent

Marie-France Pouliot, Laetitia Angers, Jean-Denys Hamel, Jean-François Paquin \*

*Canada Research Chair in Organic and Medicinal Chemistry, Département de chimie, 1045 Avenue de la Médecine, Université Laval, Québec, QC, Canada G1V 0A6*

### ARTICLE INFO

#### Article history:

Received 16 April 2012

Revised 24 May 2012

Accepted 25 May 2012

Available online 31 May 2012

### ABSTRACT

The preparation of 2-oxazolines and related N-containing heterocycles from the corresponding hydroxyamides using XtalFluor-E ( $[\text{Et}_2\text{NSF}_2]\text{BF}_4$ ) as a cyclodehydration agent is described. A wide range of heterocycles are obtained under mild conditions in good to excellent yields.

© 2012 Elsevier Ltd. All rights reserved.

#### Keywords:

Cyclodehydration reaction

Oxazolines

Heterocycles

Hydroxyamides

Diethylaminodifluorosulfonium

tetrafluoroborate

2-Oxazolines are important members of the N-containing five-membered ring family. This heterocyclic structure is used, for example, in pharmaceutical sciences,<sup>1</sup> in catalysis,<sup>2</sup> in synthetic organic chemistry,<sup>3</sup> and in material sciences.<sup>4</sup> Likewise, related heterocycles such as 2-thiazolines or 2-benzoxazoles have also attracted their share of attention in similar fields.<sup>5,6</sup> Illustrative examples of bioactive heterocycles are shown in Figure 1.

Consequently, numerous methods have been published for the preparation of these heterocycles.<sup>3,5,7</sup> Among the number of methods available to synthesize them, the cyclodehydration reaction of  $\beta$ -hydroxyamides and related derivatives is the most encountered and this transformation can be promoted by various reagents (Fig. 2).<sup>3</sup> Notably, the use of DAST and DeoxoFluor<sup>®</sup>, reagents originally developed for deoxofluorination, has been reported.<sup>7e,8</sup>

Recently, diethylaminodifluorosulfonium tetrafluoroborate ( $[\text{Et}_2\text{NSF}_2]\text{BF}_4$ ), XtalFluor-E,<sup>9</sup> has been described as a valuable alternative to DAST and DeoxoFluor<sup>®</sup> in deoxofluorination reaction due to its crystallinity and enhanced thermal stability.<sup>10</sup> We recently reported that this reagent could be used as a cyclodehydration agent for the preparation of 1,3,4-oxadiazoles from 1,2-diacylhydrazines.<sup>11</sup> Herein, we demonstrate that XtalFluor-E can also be used for the preparation of 2-oxazolines and related N-containing heterocycles from the corresponding hydroxyamides.

Optimization was performed with  $\beta$ -hydroxyamide **1a**<sup>12</sup> and initial results are reported in Table 1. Exposure of **1a** to 2 equiv

of XtalFluor-E in  $\text{CH}_2\text{Cl}_2$  at  $-78^\circ\text{C}$  followed by stirring at rt for 18 h resulted in 73% yield (entry 1). Addition of the reagent at  $0^\circ\text{C}$  gave a similar result (entry 2) while simply running the whole reaction at rt resulted in a slightly increased yield (entry 3). Heating at  $45^\circ\text{C}$  provided an improved 84% yield. Finally, changing the solvent to 1,2-dichloroethane (DCE) allowed the reaction to be performed at higher temperature. Thus, running the reaction at  $90^\circ\text{C}$  yielded 95% of the desired oxazoline **2a**. Using less XtalFluor-E (1.5 equiv) resulted in a reduced yield of 83%. In all cases,





Figure 1. Bioactive 2-oxazolines and related N-containing heterocycles.

\* Corresponding author. Tel.: +1 418 656 2131x11430; fax: +1 418 656 7916.

E-mail address: jean-francois.paquin@chm.ulaval.ca (J.-F. Paquin).

**Figure 2.** Cyclodehydration reaction of  $\beta$ -hydroxyamides and related derivatives.**Table 1**  
Initial results and optimization

Entry	Solvent	Temperature ( $^{\circ}$ C)	Yield <sup>a</sup> (%)	Reaction conditions:	
				XtalFluor-E (2 equiv.)	solvent (0.1 M) temperature, 18 h
1	CH <sub>2</sub> Cl <sub>2</sub>	–78 to rt	73		
2	CH <sub>2</sub> Cl <sub>2</sub>	0 to rt	71		
3	CH <sub>2</sub> Cl <sub>2</sub>	rt	79		
4	CH <sub>2</sub> Cl <sub>2</sub>	45	84		
5	DCE	90	95		

<sup>a</sup> Isolated yield.

examination of the crude mixtures by NMR provided no evidence of potentially competitive fluorination.<sup>13</sup>

The optimized conditions (Table 1, entry 5) were then used to examine the scope of this reaction (Table 2). A wide range of oxazolines bearing various substituents at the 2 position (*tert*-butyl, cyclohexyl, substituted phenyl rings, cinnamyl group) could be prepared in good to excellent yields (entries 1–5). An ester functional group is also well tolerated (entry 6) although slight erosion of the enantiomeric purity was observed (85% ee).<sup>14</sup> Finally, cyclization of the threonine derived hydroxyamide **1h** lead to oxazoline **2h** as a single diastereomer in 82% yield (entry 8). Mechanistically, this last result is interesting (Scheme 1). Indeed, the isolation of a single diastereomer of **2h**, which was confirmed by <sup>1</sup>H NMR,<sup>15</sup> supports a mechanism where **1h** upon reaction with XtalFluor-E, would produce an activated alcohol **3**<sup>16</sup> which undergoes cyclization via an intramolecular S<sub>N</sub>2 reaction leading to the observed diastereomer of **2h**, therefore providing an explanation for the inversion of configuration at this carbon.

Finally, we explored the possibility of using XtalFluor-E as cyclodehydration agent for the preparation of other N-containing heterocycles of interest (Table 3). Thus, cyclization of  $\beta$ -hydroxythioamide **4a**<sup>17</sup> furnished 2-thiazoline **5a** in 76% yield (entry 1). Likely, 2-benzoxazole **5b**<sup>18</sup> could be obtained in good yield from the corresponding 2-amidophenol **4b** (entry 2). Moreover, 2-oxazoline derivatives with larger ring sizes, 2-dihydro-1,3-oxazine (entry 3),<sup>7k,19</sup> and a 2-tetrahydro-1,3-oxazepine (entry 4),<sup>7k</sup> could also be prepared from the corresponding  $\gamma$ - and  $\delta$ -hydroxyamides respectively. Notably, the 55% yield for compound **5d** represents a neat improvement over the 11% yield previously reported from **4d**.<sup>7k</sup> In all cases, the desired N-containing heterocycles were isolated in moderate to excellent yields.

In conclusion, we have demonstrated that 2-oxazolines and related N-heterocycles could be obtained, in good to excellent yields, from their hydroxyamide precursors using XtalFluor-E as a cyclodehydration agent. These conditions should find use in the synthesis of these important N-containing heterocycles.

## Acknowledgments

This work was supported by the Canada Research Chair Program, the Natural Sciences and Engineering Research Council of

**Table 2**  
Preparation of 2-oxazolines


Entry	Substrate	Product	Yield <sup>a</sup> (%)	Reaction conditions:	
				XtalFluor-E (2 equiv.)	DCE (0.1 M), 90 °C, 18 h
1			95		
2			73		
3			81		
4			92		
5			83		
6			84		
7			80		
8			82		

<sup>a</sup> Isolated yield.

Canada, the Canada Foundation for Innovation, the Fonds de recherche sur la nature et les technologies (FQRNT), FQRNT Centre in Green Chemistry and Catalysis (CGCC), FQRNT Research Network on Protein Function, Structure and Engineering (PROTEO), and the Université Laval. OmegaChem is acknowledged for a generous gift of XtalFluor-E. We thank Michel A. Couturier (OmegaChem) for useful discussions and suggestions, and Alexandre l'Heureux (OmegaChem) for preliminary experiments.

## Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.tetlet.2012.05.130>.

**Scheme 1.** Mechanistic proposal for the cyclodehydration reaction.**Table 3**  
Preparation of N-containing heterocycles

Entry	Substrate	Product	Yield <sup>a</sup> (%)
1	4a-d	5a-d	
1	4a	5a	76
2	4b	5b	70
3	4c	5c	81
4	4d	5d	55

<sup>a</sup> Isolated yield.**References and notes**

- For examples, see: Li, Q.; Wood, K. W.; Claireborne, A.; Gwanlsey, S. L., II; Barr, K. J.; Liu, G.; Gehke, L.; Credo, R. B.; Hua Hui, Y.; Lee, J.; Warner, R. B.; Kovar, P.; Nukkla, M. A.; Zielinski, N. A.; Tahir, S. K.; Fitzgerald, M.; Kim, K. H.; Marsh, K.; Frost, D.; Ng, S.-C.; Rosenberg, S.; Sham, H. L. *Bioorg. Med. Chem.* **2002**, *12*, 465–469.

- Hargaden, G. C.; Giry, P. J. *Chem. Rev.* **2009**, *109*, 2505–2550.
- Wong, G. S. K.; Wu, W. In *Oxazoles: Synthesis, Reactions, and Spectroscopy, Part B*; Palmer, D. C., Ed.; John Wiley & Sons, Inc.: Hoboken, 2004; pp 331–528.
- Riobé, F.; Avarvari, N. *Coord. Chem. Rev.* **2010**, *254*, 1523–1533.
- 2-Thiazolines, see: Gaumont, A.-C.; Gulea, M.; Levillain, J. *Chem. Rev.* **2009**, *109*, 1371–1401 and references cited therein.
- 2-Benzoxazoles, see for examples: (a) Wu, Y.; Peng, X.; Fan, J.; Gao, S.; Tian, M.; Zhao, J.; Sun, S. *J. Org. Chem.* **2007**, *72*, 62–70; (b) Boyer, J.; Arnoult, E.; Médebielle, M.; Guillemont, J.; Unge, J.; Jochmans, D. *J. Med. Chem.* **2011**, *54*, 7974–7985; (c) Massue, J.; Frath, D.; Ulrich, G.; Retailleau, P.; Ziessel, R. *Org. Lett.* **2012**, *14*, 230–233.
- For selected synthetic methods, see: (a) Lafargue, P.; Guenot, P.; Lellouche, J.-P. *Heterocycles* **1995**, *41*, 947–958; (b) Wipf, P.; Venkatraman, S. *Tetrahedron Lett.* **1996**, *37*, 4659–4662; (c) Phillips, A. J.; Uto, Y.; Wipf, P.; Reno, M. J.; Williams, D. R. *Org. Lett.* **2000**, *2*, 1165–1168; (d) Bunnage, M. E.; Davies, S. G.; Goodwin, C. J. *J. Chem. Soc., Perkin Trans. 1* **1994**, *17*, 2385–2391; (e) Wuts, P. G. M.; Northuis, J. M.; Kwan, T. A. *J. Org. Chem.* **2000**, *65*, 9223–9225; (f) Kangani, C. O.; Kelley, D. E. *Tetrahedron Lett.* **2005**, *46*, 8917–8920; (g) Schwerkendiek, K.; Glorius, F. *Synthesis* **2006**, 2996–3002; (h) Kangani, C. O.; Kelley, D. E.; Day, B. W. *Tetrahedron Lett.* **2006**, *47*, 6497–6499; (i) Fan, L.; Lobkovsky, E.; Ganem, B. *Org. Lett.* **2007**, *9*, 2015–2017; (j) Chaudhry, P.; Schoenen, F.; Neuenswander, B.; Lushington, G. H.; Aubé, J. *J. Comb. Chem.* **2007**, *9*, 473–476; (k) Petersson, M. J.; Jenkins, I. D.; Loughlin, W. A. *Org. Biomol. Chem.* **2009**, *7*, 739–746; (l) Kempe, K.; Lobert, M.; Hoogenboom, R.; Schubert, U. S. *J. Comb. Chem.* **2009**, *11*, 274–280.
- (a) Burrell, G.; Evans, J. M.; Jones, G. E.; Stemp, G. *Tetrahedron Lett.* **1990**, *31*, 3649–3652; (b) Lafargue, P.; Guenot, P.; Lellouche, J.-P. *Heterocycles* **1995**, *41*, 947–958; (c) Mahler, S. G.; Serra, G. L.; Antonow, D.; Manta, E. *Tetrahedron Lett.* **2001**, *42*, 8143–8146; (d) Nicolaou, K. C.; Nevalainen, M.; Zak, M.; Bulat, S.; Bella, M.; Safina, B. S. *Angew. Chem., Int. Ed.* **2003**, *42*, 3418–3424.
- The reagent  $[\text{Et}_2\text{SF}_2]\text{BF}_4^-$  is commercially available under the trademark XtalFluor-E®.
- (a) Beaulieu, F.; Beauregard, L.-P.; Courchesne, G.; Couturier, M.; Laflamme, F.; L'Heureux, A. *Org. Lett.* **2009**, *11*, 5050–5053; (b) L'Heureux, A.; Beaulieu, F.; Bennet, C.; Bill, D. R.; Clayton, S.; Laflamme, F.; Mirmehrab, M.; Tadayon, S.; Tovell, D.; Couturier, M. *J. Org. Chem.* **2010**, *75*, 3401–3411.
- Pouliot, M.-F.; Angers, L.; Hamel, J.-D.; Paquin, J.-F. *Org. Biomol. Chem.* **2012**, *10*, 988–993.
- Aitken, R. A.; Armstrong, D. P.; Galt, R. H. B.; Mesher, S. T. *E. J. Chem. Soc., Perkin Trans. 1* **1997**, 935–943.
- De Jonghe, S.; Van Overmeire, I.; Gunst, J.; De Bruyn, A.; Hendrix, C.; Van Calenbergh, S.; Busson, R.; De Keukeleire, D.; Philippe, J.; Herdevijn, P. *Bioorg. Med. Chem. Lett.* **1999**, *9*, 3159–3164.
- Compound **2f** is prone to epimerization, see for example: Kuwano, R.; Kameyama, N.; Ikeda, R. *J. Am. Chem. Soc.* **2011**, *133*, 7312–7315.
- Ait-Haddou, H.; Hoaraou, O.; Cramailere, D.; Pezet, F.; Dara, J.-C.; Balavoine, G. G. *A. Chem. Eur. J.* **2004**, *10*, 699–707.
- Sutherland, A.; Vedera, J. C. *J. Chem. Commun.* **1999**, 1739–1740.
- McKeever, B.; Pattenden, G. *Tetrahedron* **2003**, *59*, 2713–2727.
- For selected synthetic methods, see: (a) Altenhoff, G.; Glorius, F. *Adv. Synth. Catal.* **2004**, *346*, 1661–1664; (b) Chen, Y.-X.; Qian, L.-F.; Zhang, W.; Han, B. *Angew. Chem., Int. Ed.* **2008**, *47*, 9330–9333; (c) Blacker, A. J.; Farah, M. M.; Hall, M. I.; Marsden, S. P.; Saidi, O.; Williams, J. M. *J. Org. Lett.* **2009**, *11*, 2039–2042.
- For selected synthetic methods, see: (a) Mitchell, M. A.; Benicewicz, B. C. *Synthesis* **1994**, 675–677; (b) Cwik, A.; Hell, Z.; Hegedüs, A.; Finta, Z.; Horváth, Z. *Tetrahedron Lett.* **2002**, *43*, 3985–3987.